ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Sanofi to invest $475m in new vaccine production site in Singapore

French drugmaker prepares for future pandemic with huge Asia facility

Sanofi said the new Singapore site would give it the ability to produce innovative vaccines on a massive scale for Asia and respond to future pandemic risks.   © Reuters

PARIS (Reuters) -- French drugmaker Sanofi said on Monday it would invest 400 million euros ($475.40 million) over five years in a new vaccine production site in Singapore.

The new site would provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia and respond to future pandemic risks, the company said in a statement.

The project is expected to create up to 200 local jobs, it added.

Sanofi said it expected to start the construction of the site in the third quarter of 2021 and be fully operational in the first quarter of 2026.

"The Singapore site will complement Sanofi's existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines production in Asia", the company said.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more